Stronger EBITDA despite weaker Enoxaparin sales
Sales came in line with our numbers (but above consensus), with slightly weaker performance by Enoxaparin (-11% in Q4), offset by the rest of the heparin business. In Toll Manufacturing the company included the income from the Moderna technology transfer. With gross margin slightly below expectations due to slower than expected decline in sodium heparin prices, the positive performance in terms of costs helped the company to report 83% growth in E ....
24 Feb 2021
Positive Q4 20, waiting for Moderna tailwind
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive Q4 20, waiting for Moderna tailwind
Laboratorios Farmaceuticos Rovi, S.A. (ROVI:MCE), 0 | Laboratorios Farmaceuticos Rovi, S.A. (0ILL:LON), 0
- Published:
24 Feb 2021 -
Author:
Ruiz Francisco FR -
Pages:
7
Stronger EBITDA despite weaker Enoxaparin sales
Sales came in line with our numbers (but above consensus), with slightly weaker performance by Enoxaparin (-11% in Q4), offset by the rest of the heparin business. In Toll Manufacturing the company included the income from the Moderna technology transfer. With gross margin slightly below expectations due to slower than expected decline in sodium heparin prices, the positive performance in terms of costs helped the company to report 83% growth in E ....